Dako, Amgen in companion Dx pact

Over the past few months, we've profiled a number of companion diagnostics deals between big biopharmas and diagnostic companies. This week, Denmark's Dako reported it is working with Amgen ($AMGN) on a test for a cancer drug candidate currently in clinical development. Last month, Dako announced a collaboration agreement with Amgen for the development of drug and diagnostics for cancer. "This new collaboration with Amgen underlines Dako's commitment to advance personalized medicine in cancer treatment as the selection of patients most likely to benefit from a specific treatment will increase the probability of therapeutic success for cancer patients suffering," Dako CEO Lars Holmkvist said in a statement. Dako statement

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.